Literature DB >> 25451235

An engineered dimeric fragment of hepatocyte growth factor is a potent c-MET agonist.

Cassie J Liu1, Douglas S Jones2, Ping-Chuan Tsai2, Abhishek Venkataramana2, Jennifer R Cochran3.   

Abstract

Hepatocyte growth factor (HGF), through activation of the c-MET receptor, mediates biological processes critical for tissue regeneration; however, its clinical application is limited by protein instability and poor recombinant expression. We previously engineered an HGF fragment (eNK1) that possesses increased stability and expression yield and developed a c-MET agonist by coupling eNK1 through an introduced cysteine residue. Here, we further characterize this eNK1 dimer and show it elicits significantly greater c-MET activation, cell migration, and proliferation than the eNK1 monomer. The efficacy of the eNK1 dimer was similar to HGF, suggesting its promise as a c-MET agonist.
Copyright © 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Hepatocyte growth factor; Ligand/receptor interaction; Protein engineering; Receptor agonist; Tissue regeneration; c-MET receptor

Mesh:

Substances:

Year:  2014        PMID: 25451235      PMCID: PMC4349368          DOI: 10.1016/j.febslet.2014.11.018

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  52 in total

1.  Structural basis for selective small molecule kinase inhibition of activated c-Met.

Authors:  Keith W Rickert; Sangita B Patel; Timothy J Allison; Noel J Byrne; Paul L Darke; Rachael E Ford; David J Guerin; Dawn L Hall; Maria Kornienko; Jun Lu; Sanjeev K Munshi; John C Reid; Jennifer M Shipman; Elizabeth F Stanton; Kevin J Wilson; Jonathon R Young; Stephen M Soisson; Kevin J Lumb
Journal:  J Biol Chem       Date:  2011-01-18       Impact factor: 5.157

2.  Engineered mutants of HGF/SF with reduced binding to heparan sulphate proteoglycans, decreased clearance and enhanced activity in vivo.

Authors:  G Hartmann; T Prospero; V Brinkmann; C Ozcelik; G Winter; J Hepple; S Batley; F Bladt; M Sachs; C Birchmeier; W Birchmeier; E Gherardi; O Ozcelik
Journal:  Curr Biol       Date:  1998-01-29       Impact factor: 10.834

3.  Structural basis for agonism and antagonism of hepatocyte growth factor.

Authors:  W David Tolbert; Jennifer Daugherty-Holtrop; Ermanno Gherardi; George Vande Woude; H Eric Xu
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-12       Impact factor: 11.205

4.  Utilizing the activation mechanism of serine proteases to engineer hepatocyte growth factor into a Met antagonist.

Authors:  Daniel Kirchhofer; Michael T Lipari; Lydia Santell; Karen L Billeci; Henry R Maun; Wendy N Sandoval; Paul Moran; John Ridgway; Charles Eigenbrot; Robert A Lazarus
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-19       Impact factor: 11.205

5.  Glycoprotein production for structure analysis with stable, glycosylation mutant CHO cell lines established by fluorescence-activated cell sorting.

Authors:  Sonja Wilke; Joern Krausze; Manfred Gossen; Lothar Groebe; Volker Jäger; Ermanno Gherardi; Joop van den Heuvel; Konrad Büssow
Journal:  Protein Sci       Date:  2010-06       Impact factor: 6.725

6.  Injectable extracellular matrix derived hydrogel provides a platform for enhanced retention and delivery of a heparin-binding growth factor.

Authors:  Sonya B Seif-Naraghi; Dinah Horn; Pamela J Schup-Magoffin; Karen L Christman
Journal:  Acta Biomater       Date:  2012-06-28       Impact factor: 8.947

7.  Coupling growth-factor engineering with nanotechnology for therapeutic angiogenesis.

Authors:  Rituparna Sinha Roy; Shivani Soni; Rania Harfouche; Pooja R Vasudevan; Oliver Holmes; Hugo de Jonge; Arthur Rowe; Abhimanyu Paraskar; Dirk M Hentschel; Dimitri Chirgadze; Tom L Blundell; Ermanno Gherardi; Raghunath A Mashelkar; Shiladitya Sengupta
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-16       Impact factor: 11.205

8.  A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase.

Authors:  Martin Sattler; Yuri B Pride; Patrick Ma; Jessica L Gramlich; Stephanie C Chu; Laura A Quinnan; Sheri Shirazian; Congxin Liang; Klaus Podar; James G Christensen; Ravi Salgia
Journal:  Cancer Res       Date:  2003-09-01       Impact factor: 12.701

9.  The binding properties of minimal oligosaccharides reveal a common heparan sulfate/dermatan sulfate-binding site in hepatocyte growth factor/scatter factor that can accommodate a wide variety of sulfation patterns.

Authors:  Jon A Deakin; Bärbel S Blaum; John T Gallagher; Dusan Uhrín; Malcolm Lyon
Journal:  J Biol Chem       Date:  2008-12-29       Impact factor: 5.157

10.  Insights into the structure/function of hepatocyte growth factor/scatter factor from studies with individual domains.

Authors:  O Holmes; S Pillozzi; J A Deakin; F Carafoli; L Kemp; P J G Butler; M Lyon; E Gherardi
Journal:  J Mol Biol       Date:  2007-01-26       Impact factor: 5.469

View more
  10 in total

1.  Delivery of an engineered HGF fragment in an extracellular matrix-derived hydrogel prevents negative LV remodeling post-myocardial infarction.

Authors:  Sonya B Sonnenberg; Aboli A Rane; Cassie J Liu; Nikhil Rao; Gillie Agmon; Sophia Suarez; Raymond Wang; Adam Munoz; Vaibhav Bajaj; Shirley Zhang; Rebecca Braden; Pamela J Schup-Magoffin; Oi Ling Kwan; Anthony N DeMaria; Jennifer R Cochran; Karen L Christman
Journal:  Biomaterials       Date:  2015-01-13       Impact factor: 12.479

2.  Radiation-primed hepatocyte transplantation in murine monogeneic dyslipidemia normalizes cholesterol and prevents atherosclerosis.

Authors:  Mark Barahman; Wei Zhang; Hillary Yaffe Harris; Anita Aiyer; Rafi Kabarriti; Milan Kinkhabwala; Namita Roy-Chowdhury; Amanda P Beck; Thomas S Scanlan; Jayanta Roy-Chowdhury; Patrik Asp; Chandan Guha
Journal:  J Hepatol       Date:  2019-01-14       Impact factor: 25.083

3.  A novel protein-engineered hepatocyte growth factor analog released via a shear-thinning injectable hydrogel enhances post-infarction ventricular function.

Authors:  Amanda N Steele; Lei Cai; Vi N Truong; Bryan B Edwards; Andrew B Goldstone; Anahita Eskandari; Aaron C Mitchell; Laura M Marquardt; Abbygail A Foster; Jennifer R Cochran; Sarah C Heilshorn; Y Joseph Woo
Journal:  Biotechnol Bioeng       Date:  2017-06-29       Impact factor: 4.530

4.  Cellular signaling and gene expression profiles evoked by a bivalent macrocyclic peptide that serves as an artificial MET receptor agonist.

Authors:  Wenyu Miao; Katsuya Sakai; Naoya Ozawa; Takumi Nishiuchi; Yoshinori Suzuki; Kenichiro Ito; Tomomi Morioka; Masataka Umitsu; Junichi Takagi; Hiroaki Suga; Kunio Matsumoto
Journal:  Sci Rep       Date:  2018-11-07       Impact factor: 4.379

5.  Soluble dimeric prion protein ligand activates Adgrg6 receptor but does not rescue early signs of demyelination in PrP-deficient mice.

Authors:  Anna Henzi; Assunta Senatore; Asvin K K Lakkaraju; Claudia Scheckel; Jonas Mühle; Regina Reimann; Silvia Sorce; Gebhard Schertler; Klaus V Toyka; Adriano Aguzzi
Journal:  PLoS One       Date:  2020-11-12       Impact factor: 3.240

Review 6.  Engineering growth factors for regenerative medicine applications.

Authors:  Aaron C Mitchell; Priscilla S Briquez; Jeffrey A Hubbell; Jennifer R Cochran
Journal:  Acta Biomater       Date:  2015-11-07       Impact factor: 8.947

Review 7.  Depot-Based Delivery Systems for Pro-Angiogenic Peptides: A Review.

Authors:  Amy H Van Hove; Danielle S W Benoit
Journal:  Front Bioeng Biotechnol       Date:  2015-07-16

Review 8.  Antifibrotic therapies to control cardiac fibrosis.

Authors:  Zhaobo Fan; Jianjun Guan
Journal:  Biomater Res       Date:  2016-05-25

9.  Designing Acellular Injectable Biomaterial Therapeutics for Treating Myocardial Infarction and Peripheral Artery Disease.

Authors:  Melissa J Hernandez; Karen L Christman
Journal:  JACC Basic Transl Sci       Date:  2017-04-24

Review 10.  Cyclic Peptide-Based Biologics Regulating HGF-MET.

Authors:  Hiroki Sato; Ryu Imamura; Hiroaki Suga; Kunio Matsumoto; Katsuya Sakai
Journal:  Int J Mol Sci       Date:  2020-10-27       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.